[July 28, 2016] |
|
Novocure to Host Research and Development Day on Dec. 12, 2016
Novocure (NASDAQ:NVCR) announced today that the company will hold a
research and development day for analysts and investors on Monday, Dec.
12, 2016, from 1 to 4 p.m. EST in New York City. During the event, we
plan to provide analyses from completed clinical trials, including the
full 695 patient dataset from the EF-14 trial in newly diagnosed
glioblastoma, data from the PANOVA phase 2 pilot trial in advanced
pancreatic cancer and data from the INNOVATE phase 2 pilot trial in
recurrent ovarian cancer. In addition, the company will provide an
update of recent preclinical findings related to Tumor Treating Fields
(TTFields) and a review of its ongoing clinical pipeline.
"I am very pleased with the progress we made in our clinical development
programs during the second quarter of 2016," said Asaf Danziger,
Novocure's Chief Executive Officer. "We enter the back half of the year
with a substantial liquidity position and strong preclinical data
supporting broad applicability of TTFields to multiple solid tumor
indications. With these factors in place, we are excited to share
clinical developments that will position us to expand TTFields beyond
our current glioblastoma indication. We believe that glioblastoma is
only the beginning for TTFields and Novocure, and we are dedicated to
developing this technology for patients who have such a vital need for
improved treatment options."
Dr. Eilon Kirson, Novocure's Chief Science Officer and Head of Research
and Development, will moderate the event. A live webcast will be
accessible from www.novocure.com.
Portions of the event will be available for replay on the company's
website for at least 14 days.
About Novocure Novocure is a commercial-stage oncology
company developing a novel, proprietary therapy called Tumor Treating
Fields, or TTFields, for the treatment of solid tumor cancers.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and a research
center in Haifa, Israel. For additional information about the company,
please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements In addition to historical facts
or statements of current condition, this press release may contain
forward-looking statements. Forward-looking statements provide
Novocure's current expectations or forecasts of future events. These may
include statements regarding anticipated scientific progress on its
research programs, development of potential products, interpretation of
clinical results, prospects for regulatory approval, manufacturing
development and capabilities, market prospects for its products, and
other statements regarding matters that are not historical facts. You
may identify some of these forward-looking statements by the use of
words in the statements such as "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe" or other words and terms of
similar meaning. Novocure's performance and financial results could
differ materially from those reflected in these forward-looking
statements due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K filed
on March 1, 2016, with the U.S. Securities and Exchange Commission.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not rely on
any such factors or forward-looking statements. Furthermore, Novocure
does not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak only as
of the date hereof. The Private Securities Litigation Reform Act of 1995
permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005485/en/
[ Back To TMCnet.com's Homepage ]
|